Combined hereditary disorders of haemophilia B Leyden (-6 G → A) and type 1 von Willebrand disease

Thrombosis and Haemostasis

Volumn 76, Issue 2, 1996, Pages 151-155

  Pernod, Gilles ^a   Vinciguerra, Christine ^b   Gaucher, Christine ^c   Mazurier, Claudine ^c   Polack, Benoît ^a   Négrier, Claude ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CRTS Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CHILD; DISEASE ASSOCIATION; FAMILIAL DISEASE; FEMALE; HEMOPHILIA B; HUMAN; MALE; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

EID: 0029792533     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650544     Document Type: Article

References (32)

1. Veltkamp JJ, Remmelts HG, Van Der Vlerk D, Loeliger EA. Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haematol 1970; 7: 82-90.
2. Giannelli F, Green PM, High KA, Sommer S, Poon MC, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG. Haemophilia B: database of point mutations and short additions and deletions -Fourth Edition. 1993. Nucl Acids Res 1993; 21: 3075-87.
3. Royle G, Van Der Water NS, Berry E, Ockelford PA, Browett PJ. Haemophilia B Leyden arising de novo by point mutation in the putative factor IX promoter region. Br J Haematol 1991; 77: 191-4.
4. Reitsma PH, Bertina RM, Ploos van Amstel JK, Riemens A, Briët E. The putative factor IX gene promoter in haemophilia B Leyden. Blood 1988; 72: 1074-6.
5. Ghanem N, Costes B, Martin J, Vidaud M, Rothschild C. Foyer-Gazengel C, Goossens M. Twenty four novel hemophilia B mutations revealed by rapid scanning of the whole factor IX gene in a french population sample. Eur J Hum Genet 1993; 1: 144-55.
6. Vidaud D, Tartary M, Costa JM, Bahnak BR, Gispert-Sanchez S, Fressinaud E, Gazengel C, Meyer D, Goossens M, Lavergne JM, Vidaud M. Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling. Hum Genet 1993; 91: 241-4.
7. Hirosawa S, Fahner JB, Salier JP, Wu CT, Lovrien EW, Kurachi K. Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden. Proc Natl Acad Sci 1990; 87: 4421-5.
8. Crossley M, Winship PR, Austen DEG, Riza CR, Brownlee GG. A less severe form of haemophilia B Leyden. Nucl Acids Res 1990; 18: 4633.
9. Stowell KM, Figueiredo MS, Brownlee GG, Jones P, Bolton-Maggs PHB. Haemophilia B Liverpool: a new British family with haemophilia B Leyden associated with a -6 G to A mutation in the factor IX promoter. Br J Haematol 1993; 85: 188-90.
10. Briët E, Bertina RM, Van Tilburg NH, Veltkamp JJ. Hemophilia B Leyden. A sex-linked hereditary disorder that improves after puberty. N Engl J Med 1982; 306: 788-90.
11. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257: 377-9.
12. Tavori S, Brenner B, Tatarsky I. The effect of combined factor XI deficiency with von Willebrand factor abnormalities on haemorrhagic diathesis. Thromb Haemost 1990; 63: 36-8.
13. Chediak J, Lambert E, Johnson EI, Telfer MC. Combined severe factor XI deficiency and von Willebrand's disease. Am J Clin Pathol 1980; 74: 108-14.
14. Sano M, Saito H, Shimamoto Y, Sugiura I, Ohtsubo H, Kohda H, Yamaguchi M. Combined hereditary factor XI (plasma thromboplastin antecedent) deficiency, von Willebrand's disease, and xeroderma pigmentosum in a Japanese family. Am J Hematol 1993; 44: 129-33.
15. Sanger F, Nicklen S, Coulson A. DNA sequencing with chain-termination inhibitors. Proc Natl Acad Sci Usa 1977; 74: 5463-7.
16. Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis. Thromb Haemost 1986; 55: 61-7.
17. Mercier B, Gaucher C, Mazurier C. Characterization of 98 alleles in 105 unrelated individuals in the F8vWF gene. Nucl Acids Res 1991; 19: 4800.
18. Gaucher C, Mercier B, Mazurier C. von Willebrand disease family studies: comparison of three methods of analysis of the von Willebrand factor gene polymorphism related to a variable number tandem repeat sequence in intron 40. Br J Haematol 1992; 82: 73-80.
19. Blombäck M, Eneroth P, Andersson O, Anvret M. On laboratory problems in diagnosis of mild von Willebrand's disease. Am J Hematol 1992; 40: 117-20.
20. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
21. Eikenboom JC, Reitsma PH, Peerlinck KMJ, Briët E. Recessive inheritance of von Willebrand's disease type 1. Lancet 1993; 341: 982-6.
22. Kurachi S, Furukawa M, Salier JP, Wu CT, Wilson EJ, French FS, Kurachi K. Regulatory mechanism of factor IX gene: protein binding at the Leyden-specific region. Biochem 1994; 33: 1580-91.
23. Boland EJ, Liu YC, Walter CA, Herbert DC, Weaker FJ, Odom MW, Jagadeeswaran P. Age-specific regulation of clotting factor IX gene expression in normal and transgenic mice. Blood 1995; 86: 2198-205.
24. Song CS, Rao TR, Demyan WF, Mancini MA, Chatterjee B, Roy AK. Androgen receptor messenger ribonucleic acid (mRNA) in the rat liver: changes in mRNA levels during maturation, aging, and calorie restrcition. Endocrinology 1991; 128: 349-56.
25. Picketts DJ, Lillicrap DP, Mueller CR. Synergy between transcription factors DBF and C/EBP compensates for a haemophilia B Leyden factor IX mutation. Nat Genet 1993; 3: 75-9.
26. Crossley M, Brownlee GG. Disruption of a C/EBP binding site in a factor IX promoter is associated with haemophilia B. Nature 1990; 345: 444-6.
27. Reijnen MJ, Maasdam D, Bertina RM, Reitsma PH. Haemophilia B Leyden: the effect of mutations at position + 13 on the liver-specific transcription of the factor IX gene. Blood Coag Fibrinolysis 1994; 5: 341-8.
28. Mueller CR, Maire P, Schibier U. DBP, a liver-enriched transcriptional activator, is expressed late in ontogeny and its tissue specificity is determined posttranslationally. Cell 1990; 61: 279-90.
29. Salier JP, Kurachi S, Kurachi K. Hemophilie B Leyden: les corrections naturelles d'un deficit temporaire de transcription. Med Sci 1994; 10: 186-94.
30. Poon MC, Anand S, Fraser BM, Hoar BI, Sinclair DGD. Hemophilia B carrier determination based on family-specific mutation detection by DNA single-strand conformation analysis. J Lab Clin Med 1993; 122: 5-63.
31. Coyle TE, Spicer T, Michalovic D, Poiesz BJ. Moderate hemophilia B: identification by polymerase chain reaction, sequencing, and oligomer restriction. Am J Hematol 1994; 46: 234-40.
32. Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood 1992; 79: 2507-19.